Katie Spickler
Psychiatric/Mental Health · Struthers, OHNPI 1699497156
Payments from drug & device makers
Across 270 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$908
- Vanda Pharmaceuticals Inc.$565
- Otsuka America Pharmaceutical, Inc.$489
- E.r. Squibb & Sons, L.L.C.$379
- Lundbeck LLC$344
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$334
- plus $1K from 14 others
What the payments were for
- Food & beverage$4,27098%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $908 |
| Vanda Pharmaceuticals Inc. | 33 | $565 |
| Otsuka America Pharmaceutical, Inc. | 34 | $489 |
| E.r. Squibb & Sons, L.L.C. | 11 | $379 |
| Lundbeck LLC | 24 | $344 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $334 |
| Supernus Pharmaceuticals, Inc. | 9 | $286 |
| Corium, LLC | 26 | $237 |
| Axsome Therapeutics, Inc. | 13 | $236 |
| Collegium Pharmaceutical, Inc. | 11 | $154 |
| Johnson & Johnson | 6 | $127 |
| Alkermes, Inc. | 5 | $76 |
| Neurocrine Biosciences, Inc. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Almatica Pharma LLC | 2 | $30 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Validus Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,346 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 167 | $245,335 |
| RexultiBrexpiprazole | 54 | $91,525 |
| CaplytaLumateperone Tosylate | 36 | $60,360 |
| Lurasidone Hcl | 159 | $23,957 |
| TrintellixVortioxetine Hydrobromide | 46 | $23,369 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $8,633 |
| Methylphenidate ErMethylphenidate Hcl | 40 | $7,143 |
| QelbreeViloxazine Hcl | 14 | $7,052 |
| QuviviqDaridorexant Hcl | 12 | $5,980 |
| Vilazodone Hcl | 44 | $5,916 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 139 | $5,325 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 106 | $4,082 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 78 | $3,972 |
| Buspirone Hcl | 203 | $2,564 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 16 | $2,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $908 | $245,335167 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $489 | $91,52554 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $334 | $60,36036 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $45 | $32,00170 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $286 | $7,05214 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $14 | $5,98012 claims |
| Almatica Pharma LLCSertraline Hcl | $30 | $1,576216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Struthers
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.